Stephanie Krebs - Nov 1, 2023 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Chief Business Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Nov 1, 2023
Transactions value $
$0
Form type
4
Date filed
11/2/2023, 04:53 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +125K $0.00 125K Nov 1, 2023 Common Stock 125K $0.82 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest and become exercisable as to 25% of the shares underlying the option on November 1, 2024, and the remaining 75% of the shares underlying the Option shall vest and become exercisable in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.